Max Announces Aquisition of Cellgevity
Max International has announced the acquisition of Cellgevity’s portfolio of technology and patents which continues to elevate Max’s position as the leading nutraceutical company. Cellgevity was also developing a similar product to MaxGXL called RiboCeine, a prodrug of cysteine that supports glutathione production. With the merging of the intellectual property of Max and Cellgevity we can look forward to an improved formulation of MaxGXL in the future.
Other people found this searching for:
- max cellgevity